Medicinal cannabis approvals through the Special Access Scheme fell to 8,910 in July, the second lowest monthly figure this year.
Only January has seen fewer approvals in 2022 with 8,780, according to the Therapeutic Goods Administration’s medicinal cannabis data dashboard.
The July number is 8% down on June and 20% down on the same month last year.
Oral liquid accounted for 53% of approvals, with flower at 38%.
Chronic pain and anxiety remain the most common indications, accounting for 45% and 31% respectively, followed by sleep disorders.
The number of Schedule 4 approvals totalled 1,639, representing 18% of the market, with 7,247 for Schedule 8 medicine.
The number of Authorised Prescribers (APs) had not been updated at time of publication, with 1,246 registered at the end of June. A new data dashboard specific to the AP data will be available by the end of August.
